Evidence map›Paper›PMID 31033921›Full record

ArticleOtology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology2019

[18F]fluorothymidine and [18F]fluorodeoxyglucose PET Imaging Demonstrates Uptake and Differentiates Growth in Neurofibromatosis 2 Related Vestibular Schwannoma.

Jose M Anton-Rodriguez, Daniel Lewis, Ibrahim Djoukhadar, David Russell, Peter Julyan, David Coope, Andrew T King, Simon K L Lloyd, D Gareth Evans, Alan Jackson and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[European journal of nuclear medicine and molecular imaging · 2020
    Article
  4. Malignant Mimics of Trigeminal Schwannoma.Advances in radiation oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jose M Anton-RodriguezDivision of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester.
Daniel LewisDivision of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester.
Ibrahim DjoukhadarDepartment of Neuroradiology, Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre.
David RussellDepartment of Radiology, Manchester University NHS Foundation Trust.
Peter JulyanDivision of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester.
David CoopeDivision of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester.
Andrew T KingManchester Skull Base Unit, Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust.
Simon K L LloydManchester Skull Base Unit, Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust.
D Gareth EvansManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals National Health Service Foundation Trust and Manchester Academic Health Science Centre, Manchester, UK.
Alan JacksonDivision of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester.
Julian C MatthewsDivision of Informatics, Imaging and Data Sciences, MAHSC, University of Manchester.
Salford Royal NHS Foundation Trust · GBUniversity of Manchester · GBManchester Academic Health Science Centre · GBManchester University NHS Foundation Trust · GB

Funding

Cancer Research UK C8742/A18097
6 · The paper itself

Abstract

objectiveTo investigate whether [F]fluorothymidine (FLT) and/or [F]fluorodeoxyglucose (FDG) positron emission tomography (PET) can differentiate growth in neurofibromatosis 2 (NF2) related vestibular schwannomas (VS) and to evaluate the importance of PET scanner spatial resolution on measured tumor uptake.

methodsSix NF2 patients with 11 VS (4 rapidly growing, 7 indolent), were scanned with FLT and FDG using a high-resolution research tomograph (HRRT, Siemens) and a Siemens Biograph TrueV PET-CT, with and without resolution modeling image reconstruction. Mean, maximum, and peak standardised uptake values (SUV) for each tumor were derived and the intertumor correlation between FDG and FLT uptake was compared. The ability of FDG and FLT SUV values to discriminate between rapidly growing and slow growing (indolent) tumors was assessed using receiver operator characteristic (ROC) analysis.

resultsTumor uptake was seen with both tracers, using both scanners, with and without resolution modeling. FDG and FLT uptake was correlated (R = 0.67-0.86, p < 0.01) and rapidly growing tumors displayed significantly higher uptake (SUVmean and SUVpeak) of both tracers (p < 0.05, one tailed t test). All of the PET analyses performed demonstrated better discriminatory power (AUCROC range = 0.71-0.86) than tumor size alone (AUCROC = 0.61). The use of standard resolution scanner with standard reconstruction did not result in a notable deterioration of discrimination accuracy.

conclusionNF2 related VS demonstrate uptake of both FLT and FDG, which is significantly increased in rapidly growing tumors. A short static FDG PET scan with standard clinical resolution and reconstruction can provide relevant information on tumor growth to aid clinical decision making.

Indexed as

Fluorodeoxyglucose F18AdultDideoxynucleosidesFemaleHumansMaleMiddle AgedNeurofibromatosis 2Neuroma, AcousticPositron Emission Tomography Computed TomographyRadiopharmaceuticalsYoung AdultalovudineDideoxynucleosidesFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID31033921
PMCPMC6594723
OpenAlexW2941510628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.